Publications by authors named "Ilan Rabinowitz"
Article Synopsis
- In recent studies on major depressive disorder (MDD), around 30% of patients given a placebo showed significant improvement, suggesting a strong placebo effect that is hard to minimize.
- This study aimed to explore how trial design influences the efficacy of escitalopram treatment in MDD patients by examining factors like patient and rater expectations, different outcome measures, and visit frequency.
- Results indicated that the overall response to escitalopram was similar to previous studies, regardless of trial design or participants' beliefs about their treatment, with most responders convinced they received the active medication.
High-dose escitalopram for the treatment of obsessive-compulsive disorder.
Int Clin Psychopharmacol
January 2008
The aim of this study was to evaluate the efficacy and tolerability of high-dose escitalopram in patients suffering from obsessive-compulsive disorder (OCD). In an open-label, 16-week prospective study, patients with OCD received escitalopram at a dose of 20 mg/day for 3 weeks, after a 1-week titration at 10 mg/day. Patients who did not achieve a > or =25% reduction from baseline in the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score during these 4 weeks were continued on higher doses of escitalopram (maximum 50 mg/day) for 12 weeks.
View Article and Find Full Text PDF